Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 39

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 39
---
 |     |                     |  3,250 |     |                  |  1,958 |     |                |  1,292 |     |               | * |
| Marta Wypych 43 Herbert St., Apt. 1D                    |     |                     |        |     |                  |        |     |                |        |     |               |   |
| Brooklyn, NY 11222                                      |     |                     |  9,186 |     |                  |  2,690 |     |                |  6,496 |     |               | * |
| Paulson Investment Company, LLC (17) 9171               
 Wilshire Blvd., Suite 500                               |     |                     |        |     |                  |        |     |                |        |     |               |   |
| Beverly Hills, CA 90210                                 |     |                     | 24,110 |     |                  | 17,042 |     |                |  7,068 |     |               | * |

| * | Less than 1%. |

| (1) | Represents the number of shares of Common Stock that will be beneficially owned by the selling stockholders 
 after completion of this offering based on the assumptions that (i) all of the shares of Common             |

30

| Stock registered for resale by the registration statement of which this prospectus is a part will be sold and (ii) no other shares of Common Stock will be acquired or sold by the applicable                                                           
 selling stockholders before completion of this offering. However, the selling stockholders may sell all, part or none of their shares of Common Stock offered pursuant to this prospectus and may sell all, part or none of their common stock pursuant 
 to one or more exemptions from the registration provisions of the Securities Act.                                                                                                                                                                       |

| (2) | The securities reported are held directly by the James D. Kollefrath 2017 Irrevocable Trust, and may be deemed                                                                      
 to be beneficially owned by Caroline Nyberg, as trustee. Caroline Nyberg disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein. |

| (3) | The reported securities are held directly by Norton Capital LLC (“Norton Capital”), and may be                                                                                                               
 deemed to be beneficially owned by Robert Norton, as the Manager of Norton Capital. Robert Norton disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.